Promedior IPO

promedior.com

Developer of therapeutics designed to treat fibrotic diseases. The company develops a drug discovery platform to regulate the monocyte-derived cell populations that play roles in fibrotic, inflammatory and autoimmune diseases, enabling patients with medicines to cure their diseases.

Founded2006
Total Funding to Date$76MM
Register for Details

For more details on financing and valuation for Promedior, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Promedior Ticker Symbol

Promedior does not have a ticker symbol because this company got acquired.

Promedior Stock Price

The stock price for Promedior will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).

Other companies like Promedior in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
 
 
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$1.59B
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$334.19MM